Tokyo, November 23
Remdesivir can reduce mortality in patients if administered within nine days of covid symptom onset, according to a study conducted in Asian patients.
Researchers from Tokyo Medical and Dental University (TMDU) have found that treatment with remdesivir within nine days of covid symptom onset decreases mortality in Asian patients also taking corticosteroids, the study said.
Several studies, according to the study, have already shown that remdesivir can shorten recovery time in patients with covid, although there are conflicting reports on whether the drug prevents patients from dying. In addition, previous trials did not focus on patients who required breathing support while in the ICU.
“Given the inconsistent evidence regarding the survival benefit it confers, we sought to investigate the effectiveness of remdesivir in patients with covid, who were admitted to an ICU in Japan,” said Mariko Hanafusa, first author of the study.
“All of these patients were being treated with corticosteroids for pneumonia, and some were receiving mechanical assistance for breathing,” said Hanafusa.
According to the study, the researchers analysed the medical records of 168 patients with covid admitted to the ICU at TMDU Hospital between April 2020 and November 2021. The patients were divided into groups based on whether or not they were also treated with remdesivir, the study, published in the Journal of Medical Virology, said.
“The results showed a clear difference in patient survival based on when they received treatment with remdesivir,” said Takeo Fujiwara, senior author of the study.